Antileukotriene drugs in childhood asthma: What is their place in therapy?

Paediatric Drugs

Volumn 2, Issue 5, 2000, Pages 367-372

  Selvadurai, Hiran ^a   Mellis, Craig ^a  

^a New Childrens Hospital   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; ZAFIRLUKAST; ZILEUTON;

ARTICLE; ASTHMA; DISEASE EXACERBATION; DISEASE MANAGEMENT; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DYSPEPSIA; EXERCISE INDUCED ASTHMA; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; LIVER TOXICITY; LUNG FUNCTION; PHARYNGITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH;

ASTHMA; CHILD; HUMAN; LEUKOTRIENE ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS;

EID: 0033809683     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200002050-00004     Document Type: Article

References (24)

1. Leukotrienes and inflammation
2. The role of leukotriene modifiers in the treatment of asthma
3. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma
4. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma
5. 13 week disease response study with zafirlukast in patents with mild to moderate asthma
6. Effects of 13 weeks of treatment with ICI 20,219 (accolate) or cromolyn sodium in patients with mild to moderate asthma
7. Montelukast, a leukotriene receptor antagonist for the treatment of mild asthma and exercise induced bronchoconstriction
8. Increased urinary excretion of LTE after exercise and attenuation of exercise induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist
9. The leukotriene D4 receptor antagonist zafirlukast attenuates exercise induced bronchoconstriction in children
10. Oral montelukast compared with inhaled salmeterol to prevent exercise induced bronchoconstriction: A randomised double blind trial
11. Montelukast for chronic asthma in 6 to 14 year old children: A randomised double blind trial
12. Montelukast, a once daily leukotriene receptor antagonist, in the treatment of chronic asthma: A multicenter randomised double blind trial
13. Effects of montelukast, a potent cysteinyl leukotriene receptor antagonist on bronchodilation in asthmatic subjects treated with and without inhaled steroids
14. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 antagonist in subjects with bronchial asthma
15. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma
16. Leukotriene antagonists prevent exacerbation of asthma during reduction of high dose inhaled steroid
17. The effect of inhibition of 5-lipoxygenase by zileuton in mild to moderate asthma
18. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: A 6 month randomised multicenter trial
19. The comparative effect of zileuton, a 5-lipoxygenase inhibitor plus low dose inhaled beclomethasone vs higher dose beclomethasone for asthma
20. Montelukast added to inhaled beclomethasone in treatment of asthma
21. Asthma drug linked with Churg-Strauss syndrome
22. Churg Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment